Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone vs eplerenone on metabolic profile in heart failure with reduced LVEF
IRCT20240823062849N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of spironolactone and eplerenone in heart failure (HF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Iran University of Medical Sciences. Started May 2024; status: completed.
02
Drugs
spironolactoneeplerenone
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20240823062849N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240823062849N1.